Picture: European Chemistry Partnering

Six times as many decision-makers attended the 3rd European Chemistry Partnering today- compared to the initial event two years ago: with participants from Brazil, Morocco and Australia, all six continents were represented for the first time. More than 2,000 partnering meetings formed the basis of interdisciplinary exchanges regarding innovation. In addition, there were countless discussions in the exhibition area, at the speaker corners and during the many networking opportunities.

©  123rf.com/Charnsit Ramyarupa

Researchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation.

© 123rf.com/Denphumi Jaisue

University Zurich spin-off Anaveon AG announced it will proceeds from its financing round to push development of its preclinical IL-2-receptor agonist.

© CDC

The global antibacterial innovation network CARB-X has expanded its reach by adding six new life-science organisations to its fight against antimicrobial resistance (AMR). 

Roche tower at Basel headquarters. ©123rf.com/ Pavel Dudek

Swiss pharma giant Roche has complemented its drug pipeline in the lucrative hemophilia A market by taking over hemophilia A gene therapy developer Spark Therapeutics for US$4.3bn.

© 123rf.com/Julia Sudnitskaya

Sodium chloride can promote immune responses that have been linked to atopic dermatitis. Researchers have now unraveled the mechanistic details between salt intake and activation of T cells.

© Calypso Biotech BV

Dutch autoimmunity specialist Calypso Biotech BV has raised €20m in a Series A financing co-led by Gilde Healthcare and Inkef Capital and co-financed by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and the company’s seed investor M Ventures.

© 123rf_ Christoph Burgstedt

Evotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in order to find novel resistance-breaking antibiotics against Gram-negative bugs.

Human heart muscle cells derived from triple-engineered stem cells that are invisible to the immune system. The red is troponin, a protein that participates in cardiac muscle contraction. The blue is the cell's nucleus. Researchers hope cells like these will eventually be used to treat heart failure. © USCF/ Xiaomeng Hu.

Researchers for the first time have found a way to prevent immune rejection of allogenic iPSC-derived cell and tissue transplants. 

Picture: DHL/Accenture

It‘s only been nine years since the first blockchain technology applications in finance were introduced. Big players are now working to use distributed computing to protect pharma logistics from counterfeit drugs. Unlike current Internet-based solutions, the decentralised blockchain network is immune to manipulation or hacks, as transactions can be verified, recorded, and coordinated autonomously without third-party involvement.